Brief: Upstream Bio Announces First Patient Dosed In Phase 2 Clinical Trial Of Verekitug
08/07/2025 12:26
July 8 (Reuters) - Upstream Bio Inc UPB.O: UPSTREAM BIO ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 CLINICAL TRIAL OF VEREKITUG IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) UPSTREAM BIO INC - DOSES FIRST PATIENT IN PHASE 2 COPD TRIAL Source text: ID:nGNX6N63TQ Further company coverage: UPB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Upstream Bio
See all newsUpstream Bio Q2 net loss narrows slightly on lower R&D costs
Upstream Bio Inc expected to post a loss of 76 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Adobe, Caseys General Stores, Oracle
Brief: Upstream Bio To Showcase Additional Efficacy Data From The Phase 2 Vibrant Trial Of Verekitug In Crswnp In Oral Session At Eaaci 2026
Upstream Bio Q1 net loss widens on higher R&D costs